June #188 : Cure: Gene Therapy Has HIV in a Bind - by Benjamin Ryan

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents
 

Features

The Sound of Stigma

Artful Warriors

From the Editor

We Are Family

Feedback

Letters-June 2013

The POZ Q+A

Out of the Shadows

POZ Planet

Beyond the Pale

Koch vs. Koop

The New 'Normal'

Fountain of Youth

National HIV Coming Out Day?

To Be Continued

In the Beginning

R.I.P. NAPWA

Voices

Immigration Status

Care and Treatment

GMHC Treatment Issues June 2013

Generics Save Money but May Come With Risks

TasP Movement Gains Momentum

PIs in First Trimester Linked to Premature Births

Child 'Functionally Cured' of HIV?

Research Notes

Prevention: New Understanding of Old Vaccine

Treatment: CD4 Tests Needed Only Yearly?

Cure: Gene Therapy Has HIV in a Bind

Concerns: Health Threats Outside of AIDS

POZ Survey Says

The Doctor Is In

POZ Heroes

Trailblazer

   
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


email print

June 2013

Cure: Gene Therapy Has HIV in a Bind

by Benjamin Ryan

Stanford scientists have created a new way to manipulate the genes of CD4 cells in order to buffer them against HIV infection. HIV enters CD4s by first binding to either the CCR5 or CXCR4 receptors on the cells’ surface. The scientists created a splice in the DNA of the CCR5 receptor and added three new genes to create multiple layers of resistance to HIV, helping to block the virus’s entry through both the CCR5 and CXCR4 receptors. Testing the gene therapy in a lab setting, the Stanford researchers inserted one, two or all three genes into CD4s. Those cells that received the triple modification had more than a 1,200-fold protection against HIV molecules that use the CCR5 receptor for entry (called “CCR5-tropic”) and a 1,700-fold protection against CXCR4-tropic HIV.

Search: Stanford, gene therapy, CCR5 receptors, CXCR4 receptors

Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Poll
Should the U.S. gay blood ban end?
Yes
No

Survey
Smoke Signals

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.